Comparative Pharmacology
Head-to-head clinical analysis: LERITINE versus MEPERGAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LERITINE versus MEPERGAN.
LERITINE vs MEPERGAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LERITINE (anileridine) is a synthetic opioid analgesic that acts as a mu-opioid receptor agonist, modulating pain perception and emotional response to pain.
Meperidine is a synthetic opioid agonist that binds to mu-opioid receptors in the central nervous system, mimicking endogenous endorphins to produce analgesia. Promethazine is a phenothiazine antipsychotic that antagonizes histamine H1, dopamine D2, muscarinic acetylcholine, and alpha-adrenergic receptors, providing sedation and antiemetic effects.
Adults: 25-50 mg orally every 6 hours as needed for pain; not to exceed 200 mg/day.
Meperidine 50-100 mg and promethazine 25-50 mg IM/IV every 3-4 hours as needed. Maximum meperidine dose: 600 mg/day.
None Documented
None Documented
2-3 hours (terminal half-life in adults; may be prolonged in hepatic impairment or elderly, dosing adjustments recommended)
Meperidine: 3-4 hours (terminal; increased in hepatic impairment). Promethazine: 9-16 hours (terminal; prolonged in elderly).
Renal (70-90% as unchanged drug and metabolites); biliary/fecal (10-30%)
Renal elimination of metabolites (meperidine: ~90% as metabolites, <5% unchanged; promethazine: ~70-80% as metabolites, <1% unchanged). Biliary/fecal excretion is minimal (<10% for both).
Category C
Category C
Opioid Analgesic
Opioid Analgesic/Antiemetic Combination